-
1.发明授权Derivatives of urea and related diamines, methods for their manufacture, and uses therefor 有权脲和相关二胺的衍生物，其制造方法及其用途公开(公告)号：US08324396B2
公开(公告)日：2012-12-04
申请号：US12218228
申请日：2008-07-10
申请人： Pierre Deprez , Christopher Fotsch , Paul Harrington , Sarah Lively , Kanaka Pattabiraman , David St. Jean , Taoues Temal-Laib
发明人： Pierre Deprez , Christopher Fotsch , Paul Harrington , Sarah Lively , Kanaka Pattabiraman , David St. Jean , Taoues Temal-Laib
IPC分类号： C07D277/32 , A61K31/425
CPC分类号： C07D277/82 , C07D277/46 , C07D417/12 , C07D417/14
摘要： The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders related to the function of the calcium sensing receptor. The invention also relates to processes for making such compounds and to intermediates useful in these processes.
摘要翻译： 本发明一般涉及式I所示的化合物，包含它们的药物组合物以及治疗与钙敏感受体的功能有关的疾病或病症的方法。 本发明还涉及制备这些化合物和在这些方法中有用的中间体的方法。
-
2.发明申请Derivatives of urea and related diamines, methods for their manufacture, and uses therefor 有权脲和相关二胺的衍生物，其制造方法及其用途公开(公告)号：US20090054463A1
公开(公告)日：2009-02-26
申请号：US12218228
申请日：2008-07-10
申请人： Pierre Deprez , Christopher Fotsch , Paul Harrington , Sarah Lively , Kanaka Pattabiraman , David St. Jean , Taoues Temal-Laib
发明人： Pierre Deprez , Christopher Fotsch , Paul Harrington , Sarah Lively , Kanaka Pattabiraman , David St. Jean , Taoues Temal-Laib
IPC分类号： A61K31/506 , C07D277/82 , C07D277/12 , C07D417/02 , C07D417/12 , C07D401/12 , A61P5/14 , A61K31/426 , A61K31/427 , A61K31/4439 , A61K31/497
CPC分类号： C07D277/82 , C07D277/46 , C07D417/12 , C07D417/14
摘要： The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders related to the function of the calcium sensing receptor. The invention also relates to processes for making such compounds and to intermediates useful in these processes.
摘要翻译： 本发明一般涉及式I所示的化合物，包含它们的药物组合物以及治疗与钙敏感受体的功能有关的疾病或病症的方法。 本发明还涉及制备这些化合物和在这些方法中有用的中间体的方法。
-
公开(公告)号：US08530476B2
公开(公告)日：2013-09-10
申请号：US12557650
申请日：2009-09-11
IPC分类号： A61K31/497 , C07D403/00 , C07D405/06 , C07D401/06
CPC分类号： C07D295/195 , C07D207/335 , C07D209/08 , C07D209/14 , C07D209/82 , C07D211/16 , C07D213/38 , C07D213/56 , C07D213/61 , C07D213/75 , C07D215/12 , C07D215/18 , C07D239/42 , C07D241/42 , C07D295/20 , C07D295/215 , C07D307/79 , C07D307/81 , C07D317/46 , C07D317/58 , C07D319/16 , C07D319/18 , C07D333/58 , C07D333/60 , C07D401/12 , C07D405/12 , C07D417/12
摘要： Certain piperazinyl and piperidinyl urea compounds are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).
-
4.发明授权Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase 有权哌嗪基和哌啶基脲作为脂肪酸酰胺水解酶的调节剂公开(公告)号：US07598249B2
公开(公告)日：2009-10-06
申请号：US11321710
申请日：2005-12-29
IPC分类号： A61K31/497 , A61K31/445 , A01N43/40 , C07D241/04 , C07D211/00 , C07D295/00
CPC分类号： C07D295/195 , C07D207/335 , C07D209/08 , C07D209/14 , C07D209/82 , C07D211/16 , C07D213/38 , C07D213/56 , C07D213/61 , C07D213/75 , C07D215/12 , C07D215/18 , C07D239/42 , C07D241/42 , C07D295/20 , C07D295/215 , C07D307/79 , C07D307/81 , C07D317/46 , C07D317/58 , C07D319/16 , C07D319/18 , C07D333/58 , C07D333/60 , C07D401/12 , C07D405/12 , C07D417/12
摘要： Certain piperazinyl and piperidinyl urea compounds are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).
摘要翻译： 某些哌嗪基和哌啶基脲化合物可用作FAAH抑制剂。 此类化合物可用于治疗由脂肪酰胺水解酶（FAAH）活性介导的疾病状态，病症和病症的药物组合物和方法。 因此，可以施用化合物以治疗例如焦虑，疼痛，炎症，睡眠障碍，进食障碍或运动障碍（例如多发性硬化症）。
-
公开(公告)号：US07169814B2
公开(公告)日：2007-01-30
申请号：US10318278
申请日：2002-12-11
申请人： Jonathan B. Rothbard , Paul A. Wender , Kanaka Pattabiraman , Erin T. Pelkey , Theodore C. Jessop
发明人： Jonathan B. Rothbard , Paul A. Wender , Kanaka Pattabiraman , Erin T. Pelkey , Theodore C. Jessop
IPC分类号： A61K31/155
CPC分类号： A61K47/54
摘要： Transport reagents and conjugates of therapeutic agents linked to transport reagents are described. In particular, the transport reagents have a plurality of guanidinium moieties that are either contiguous or spaced along a backbone, but are sufficiently removed from the backbone via tethers, to allow their interaction with a cell or tissue surface, leading to uptake of the therapeutic agent.
摘要翻译： 描述了与运输试剂连接的治疗剂的转运试剂和缀合物。 特别地，转运试剂具有多个与骨架连续或间隔的胍部分，但是通过系链从骨架中充分除去，以允许它们与细胞或组织表面相互作用，导致治疗剂的摄取 。
-
6.发明申请PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE 有权作为脂肪酸酰胺水解酶的调节剂的哌嗪和哌啶酸公开(公告)号：US20100004261A1
公开(公告)日：2010-01-07
申请号：US12557650
申请日：2009-09-11
IPC分类号： A61K31/496 , C07D401/12 , C07D401/14 , C07D417/14 , A61P25/00 , A61P25/22 , A61P29/00 , A61P3/00 , A61P25/28 , A61P25/08 , A61P1/00 , A61P27/02 , A61P25/16 , A61P27/06 , A61P31/18 , A61P31/00 , A61P19/02 , A61P9/00 , A61P9/12 , A61P35/00 , A61P11/00 , A61P15/00 , A61P15/04 , A61P17/04
CPC分类号： C07D295/195 , C07D207/335 , C07D209/08 , C07D209/14 , C07D209/82 , C07D211/16 , C07D213/38 , C07D213/56 , C07D213/61 , C07D213/75 , C07D215/12 , C07D215/18 , C07D239/42 , C07D241/42 , C07D295/20 , C07D295/215 , C07D307/79 , C07D307/81 , C07D317/46 , C07D317/58 , C07D319/16 , C07D319/18 , C07D333/58 , C07D333/60 , C07D401/12 , C07D405/12 , C07D417/12
摘要： Certain piperazinyl and piperidinyl urea compounds are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).
摘要翻译： 某些哌嗪基和哌啶基脲化合物可用作FAAH抑制剂。 此类化合物可用于治疗由脂肪酰胺水解酶（FAAH）活性介导的疾病状态，病症和病症的药物组合物和方法。 因此，可以施用化合物以治疗例如焦虑，疼痛，炎症，睡眠障碍，进食障碍或运动障碍（例如多发性硬化症）。
-
7.发明授权N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase 有权N-杂芳基哌嗪基脲作为脂肪酸酰胺水解酶的调节剂公开(公告)号：US07541359B2
公开(公告)日：2009-06-02
申请号：US11478128
申请日：2006-06-28
IPC分类号： A61K31/496 , A61K31/505 , A61K31/5377 , C07D285/135 , C07D417/04 , C07D417/12
CPC分类号： C07D285/08 , C07D417/04 , C07D417/12 , C07D417/14
摘要： Certain N-heteroarylpiperazinyl urea compounds of Formula (I), as defined in the specification, are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).
摘要翻译： 描述了如说明书中定义的某些式（I）的N-杂芳基哌嗪基脲化合物，其可用作FAAH抑制剂。 此类化合物可用于治疗由脂肪酰胺水解酶（FAAH）活性介导的疾病状态，病症和病症的药物组合物和方法。 因此，可以施用化合物以治疗例如焦虑，疼痛，炎症，睡眠障碍，进食障碍或运动障碍（例如多发性硬化症）。
-
8.发明申请N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase 有权N-杂芳基哌嗪基脲作为脂肪酸酰胺水解酶的调节剂公开(公告)号：US20070004741A1
公开(公告)日：2007-01-04
申请号：US11478128
申请日：2006-06-28
IPC分类号： A61K31/506 , A61K31/497 , A61K31/496 , C07D417/14 , C07D417/04
CPC分类号： C07D285/08 , C07D417/04 , C07D417/12 , C07D417/14
摘要： Certain N-heteroarylpiperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).
摘要翻译： 描述了某些N-杂芳基哌嗪基脲化合物，其可用作FAAH抑制剂。 此类化合物可用于治疗由脂肪酰胺水解酶（FAAH）活性介导的疾病状态，病症和病症的药物组合物和方法。 因此，可以施用化合物以治疗例如焦虑，疼痛，炎症，睡眠障碍，进食障碍或运动障碍（例如多发性硬化症）。
-
公开(公告)号：US20060173184A1
公开(公告)日：2006-08-03
申请号：US11321710
申请日：2005-12-29
IPC分类号： C07D403/02
CPC分类号： C07D295/195 , C07D207/335 , C07D209/08 , C07D209/14 , C07D209/82 , C07D211/16 , C07D213/38 , C07D213/56 , C07D213/61 , C07D213/75 , C07D215/12 , C07D215/18 , C07D239/42 , C07D241/42 , C07D295/20 , C07D295/215 , C07D307/79 , C07D307/81 , C07D317/46 , C07D317/58 , C07D319/16 , C07D319/18 , C07D333/58 , C07D333/60 , C07D401/12 , C07D405/12 , C07D417/12
摘要： Certain piperazinyl and piperidinyl urea compounds are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).
-
公开(公告)号：US20060264608A1
公开(公告)日：2006-11-23
申请号：US11375795
申请日：2006-03-14
CPC分类号： C07C271/22 , C07C277/08 , C07C279/10 , C07K1/006
摘要： Synthesis routes that can be adapted to large scale synthesis of oligoguanidine compounds such as oligoarginine compounds are described which use a perguanidinylation step to convert a group of ω-amino groups to the corresponding guanidinyl groups. These compounds find utility as transport agents. Modified oligoguanidine compounds are also described.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.043 秒)
